EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial

Pieter C Smits, Adrian Włodarczak, Bernard Chevalier, Nick E J West, Tommaso Gori, Mohamed Abdel-Wahab, Emanuele Barbato, Giovanni Esposito, Giuseppe Tarantini, Viktor Kocka, Stephan Achenbach, Dariusz Dudek und 8 weitere

EuroIntervention · 2026-02 · 22 (4) · 243-254

DOI: 10.4244/eij-d-25-00778 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2026-02. Verfasst von Pieter C Smits und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Absorbable Implants, Coronary Restenosis, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The clinical outcomes of bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents (EES) beyond 5-year follow-up are unknown. AIMS: This study aims to investigate clinical outcomes of BVS 7 years after implantation. METHODS: The COMPARE-ABSORB trial is an investigator-initiated, prospective randomised study. Patients at high risk of restenosis were randomly assigned to receive either a BVS or an EES. A dedicated implantation technique was recommended for BVS. The primary endpoint was target lesion failure (TLF), defined as the composite of cardiac death, target vessel myocardial infarction (TVMI), or clinically indicated target lesion revascularisation (CI-TLR). The primary and co-primary objectives were non-inferiority at 1 year and superiority of BVS at 7 years after a 3-year landmark analysis. RESULTS: Although enrolment was stopped at 1,670 patients (80% of the intended 2,100 patients; 848 patients receiving BVS and 822 EES) because of high thrombosis and TVMI rates in the BVS arm, non-inferiority for TLF at 1 year was met. At 7-year follow-up subsequent to a 3-year landmark analysis, the TLF rate of BVS was 6.7% versus 5.9% for EES (hazard ratio [HR] 1.14, 95% confidence interval [CI]: 0.76-1.77; p=0.53); therefore, superiority was not met. Cardiac death, TVMI, and device thrombosis rates did not differ between both groups; however, CI-TLR was significantly higher in the BVS arm (4.4% vs 2.2%; HR 1.97, 95% CI: 1.08-3.60; p=0.023). CONCLUSIONS: After complete resorption, no benefit was observed with BVS compared with EES at 7-year follow-up, despite the use of a dedicated implantation protocol for BVS. In fact, after 3 years, more target lesion revascularisations occurred with BVS than with EES.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsAbsorbable ImplantsCoronary RestenosisPercutaneous Coronary InterventionCoronary Artery DiseaseTissue ScaffoldsHumansFemaleMaleMiddle AgedAgedTreatment OutcomeEverolimusProspective StudiesMyocardial InfarctionRisk FactorsProsthesis Design

Substanzen

Everolimus

Autor:innen und Institutionen

  • Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.
  • Cardiovascular European Research Center, Massy, France and ICPS, Massy, France.
  • Department of Cardiology, Miedziowe Centrum Zdrowia, Lubin, Poland and Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland.
  • Ramsay Générale de Santé, ICPS, Hôpital Jacques Cartier, Massy, France.
  • Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom.
  • Center of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, and DZHK Standort Rhein-Main, Mainz, Germany.

Zitieren

APA

Smits, P. C., Włodarczak, A., Chevalier, B., West, N. E. J., Gori, T., Abdel-Wahab, M., Barbato, E., Esposito, G., Tarantini, G., Kocka, V., Achenbach, S., Dudek, D., Escaned, J., Tijssen, J. G. P., Rademaker-Havinga, T. A. M., Serruys, P., Morice, M. C., Onuma, Y., Geuns, R. V., & Behalf Of The Compare-Absorb Trial Investigators, O. (2026). Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial. EuroIntervention, 22(4), 243-254. https://doi.org/10.4244/eij-d-25-00778

Vancouver

Smits PC, Włodarczak A, Chevalier B, West NEJ, Gori T, Abdel-Wahab M, et al. Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial. EuroIntervention. 2026;22(4):243-254. doi:10.4244/eij-d-25-00778

BibTeX
@article{Smits2026,
  author = {Smits, Pieter C and Włodarczak, Adrian and Chevalier, Bernard and West, Nick E J and Gori, Tommaso and Abdel-Wahab, Mohamed and Barbato, Emanuele and Esposito, Giovanni and Tarantini, Giuseppe and Kocka, Viktor and Achenbach, Stephan and Dudek, Dariusz and Escaned, Javier and Tijssen, Jan G P and Rademaker-Havinga, Tessa A M and Serruys, Patrick and Morice, Marie-Claude and Onuma, Yoshinobu and Geuns, Robert-Jan van and Behalf Of The Compare-Absorb Trial Investigators, On},
  title = {Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial},
  journal = {EuroIntervention},
  year = {2026},
  volume = {22},
  number = {4},
  pages = {243--254},
  doi = {10.4244/eij-d-25-00778}
}
Kostenlos starten →